Ingenix was founded in 2023 and is headquartered in Warsaw. The company develops the Biological Reasoning Engine, an AI system built on a Modality Fusion architecture that integrates best-in-class models across modalities and biological scales and reasons across their representations. Outputs from the Engine include a reasoning trace that lays out mechanism, evidence, and caveats alongside conclusions for translational and clinical R&D decision-making. Ingenix said the Engine produced candidate ADC payload combinations for an oncology biotech in minutes, including novel hypotheses and several actionable candidates. The company plans to broaden work with pharma and biotech partners through a newly launched Qualified Access Program. Financially, Ingenix raised a €13m seed-extension round led by Sofinnova Partners with participation from Inovo VC and OTB VC to scale the Engine and expand partner engagements.

Total raised

$26M

Funding rounds

2

Latest round

Seed

Latest activity

Jun 2026